Human CA9 PharmaGenie ELISA Kit (SBRS0340)

Carbonic anhydrase 9 (CA9) is a hypoxia-inducible transmembrane enzyme widely studied as a biomarker for renal cell carcinoma, cervical cancer, and other solid tumors shaped by tumor hypoxia. This quantitative human immunoassay from Assay Genie enables researchers to measure CA9 protein levels in biological specimens, supporting investigations of the tumor microenvironment, HIF-1 signaling, and response to therapy.

The kit accepts cell culture supernatants, plasma, and serum samples, making it adaptable to both in vitro cell-based experiments and translational research workflows. Reagents are provided in a 96-assay plate format, delivering enough material for routine screening of patient cohorts or culture panels while keeping per-sample consumption efficient.

Laboratories focused on clear cell renal cell carcinoma, head and neck cancers, or the pharmacology of carbonic anhydrase inhibitors will find this kit a practical tool for correlating CA9 expression with disease stage, treatment outcome, or experimental manipulation of hypoxic pathways.